Emcure Pharmaceuticals Limited (NSE:EMCURE)
1,674.80
+31.80 (1.94%)
May 11, 2026, 3:30 PM IST
Emcure Pharmaceuticals Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 1,475 | 1,555 | 1,690 | 2,423 | 1,628 |
Short-Term Investments | - | 760.43 | 2,997 | 2,045 | - |
Cash & Short-Term Investments | 1,475 | 2,316 | 4,687 | 4,468 | 1,628 |
Cash Growth | -36.30% | -50.59% | 4.88% | 174.38% | -66.33% |
Accounts Receivable | 25,627 | 20,022 | 18,588 | 16,483 | 13,085 |
Other Receivables | 687.38 | 531.97 | 731.86 | 703.62 | 461.91 |
Receivables | 26,314 | 20,554 | 19,320 | 17,187 | 13,547 |
Inventory | 23,979 | 19,885 | 15,891 | 14,593 | 15,593 |
Prepaid Expenses | - | 326.05 | 304.41 | 198.6 | 330.53 |
Other Current Assets | 4,353 | 2,477 | 2,397 | 1,912 | 3,142 |
Total Current Assets | 56,121 | 45,559 | 42,599 | 38,359 | 34,241 |
Property, Plant & Equipment | 24,908 | 24,271 | 23,972 | 22,148 | 19,855 |
Long-Term Investments | 197.03 | 221.26 | 199.85 | 557.78 | 440.37 |
Goodwill | 4,143 | 3,678 | 3,787 | 2,177 | 2,174 |
Other Intangible Assets | 6,868 | 5,792 | 5,078 | 1,258 | 1,614 |
Long-Term Deferred Tax Assets | 1,394 | 1,110 | 967.96 | 991.26 | 1,161 |
Other Long-Term Assets | 2,494 | 1,696 | 1,458 | 1,234 | 1,150 |
Total Assets | 96,125 | 82,327 | 78,062 | 66,725 | 60,635 |
Accounts Payable | 18,078 | 14,796 | 13,094 | 10,861 | 11,252 |
Accrued Expenses | 722.64 | 2,571 | 2,418 | 2,782 | 2,457 |
Short-Term Debt | 9,519 | 4,747 | 9,486 | 11,333 | 10,866 |
Current Portion of Long-Term Debt | - | 670.79 | 3,721 | 3,175 | 2,797 |
Current Portion of Leases | 548.78 | 337.28 | 319.19 | 241.9 | 222.96 |
Current Income Taxes Payable | 1,430 | 1,123 | 534.45 | 487.75 | 621.52 |
Current Unearned Revenue | - | - | - | 178.65 | 271.39 |
Other Current Liabilities | 8,825 | 2,438 | 2,532 | 1,132 | 1,160 |
Total Current Liabilities | 39,122 | 26,683 | 32,105 | 30,192 | 29,648 |
Long-Term Debt | 2,522 | 1,899 | 7,666 | 7,441 | 7,173 |
Long-Term Leases | 2,623 | 2,573 | 2,157 | 1,152 | 1,113 |
Long-Term Unearned Revenue | 73.04 | 300.25 | 403.08 | 307.32 | 393.7 |
Long-Term Deferred Tax Liabilities | 980 | 1,200 | 1,374 | 388.95 | 426.14 |
Other Long-Term Liabilities | 1,038 | 3,256 | 3,139 | 747.37 | 739.54 |
Total Liabilities | 46,358 | 35,912 | 46,844 | 40,229 | 39,493 |
Common Stock | 1,896 | 1,895 | 1,812 | 1,809 | 1,809 |
Additional Paid-In Capital | - | 7,853 | 98.84 | - | - |
Retained Earnings | - | 33,767 | 26,980 | 22,789 | 17,751 |
Comprehensive Income & Other | 47,604 | 947.24 | 632.25 | 413.54 | 315.91 |
Total Common Equity | 49,500 | 44,462 | 29,523 | 25,011 | 19,875 |
Minority Interest | 266.41 | 1,954 | 1,695 | 1,485 | 1,266 |
Shareholders' Equity | 49,767 | 46,416 | 31,218 | 26,497 | 21,141 |
Total Liabilities & Equity | 96,125 | 82,327 | 78,062 | 66,725 | 60,635 |
Total Debt | 15,212 | 10,227 | 23,350 | 23,343 | 22,172 |
Net Cash (Debt) | -13,737 | -7,912 | -18,663 | -18,875 | -20,544 |
Net Cash Per Share | -72.48 | -42.30 | -103.18 | -104.37 | -113.59 |
Filing Date Shares Outstanding | 189.57 | 189.48 | 181.15 | 180.85 | 180.85 |
Total Common Shares Outstanding | 189.57 | 189.48 | 181.15 | 180.85 | 180.85 |
Working Capital | 16,999 | 18,876 | 10,494 | 8,167 | 4,593 |
Book Value Per Share | 261.12 | 234.65 | 162.97 | 138.30 | 109.90 |
Tangible Book Value | 38,489 | 34,992 | 20,658 | 21,576 | 16,088 |
Tangible Book Value Per Share | 203.04 | 184.67 | 114.04 | 119.30 | 88.96 |
Land | - | 529.12 | 526.46 | 533.22 | 522.55 |
Buildings | - | 6,199 | 5,953 | 5,478 | 4,901 |
Machinery | - | 27,491 | 25,498 | 20,713 | 18,271 |
Construction In Progress | - | 1,241 | 1,323 | 4,035 | 3,098 |
Leasehold Improvements | - | 656.11 | 583.3 | 368.83 | 324.63 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.